Sign up
Pharma Capital

Motif Bio on track to move forward with new drug application after Iclaprim success

Graham Lumsden, chief executive of Motif Bio Plc (LON:MTFB, NASDAQ: MTFB) tells Proactive he's 'very pleased' their lead drug Iclaprim has successfully navigated its way through  a crucial final-stage clinical study.

Lumsden says their big focus now is lodging a new drug application with US regulators which'll happen in the first quarter of next year.


View full MTFB profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.